NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

NEW YORK – With new data and plans for additional clinical validation in the works, liquid biopsy firm PanGia Biotech is making strides toward commercialization of its urine-based prostate cancer ...

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

NEW YORK — Gut microbiome health startup 32 Biosciences said on Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products.

NEW YORK – Quest Diagnostics said Tuesday that it is collaborating with the University of Texas MD Anderson Cancer Center to develop and validate a laboratory-developed test to identify individuals ...